Iloprost for prevention of contrast-mediated nephropathy in high-risk patients undergoing a coronary procedure. Results of a randomized pilot study

European Journal of Clinical Pharmacology

Volumn 62, Issue 8, 2006, Pages 589-595

  Spargias, K ^a,b   Adreanides, E ^a   Giamouzis, G ^a   Karagiannis, S ^a   Gouziouta, A ^a   Manginas, A ^a   Voudris, V ^a   Pavlides, G ^a   Cokkinos, D V ^a  

^a Onassis Heart Centre   (Greece)

^b NONE   (Greece)

Author keywords

Contrast nephropathy; Coronary angiogrphy; Iloprost; Prostacyclin; Prostaglandins

Indexed keywords

CONTRAST MEDIUM; CREATININE; ILOPROST; PLACEBO;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BLEEDING; CARDIOVASCULAR PROCEDURES; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTRAST MEDIATED NEPHROPATHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; FLUSHING; HIGH RISK PATIENT; HUMAN; HYPOTENSION; KIDNEY DISEASE; LOW DRUG DOSE; MALE; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL ANALYSIS;

AGED; CONTRAST MEDIA; CORONARY ANGIOGRAPHY; CREATININE; FEMALE; HUMANS; ILOPROST; KIDNEY DISEASES; MALE; PILOT PROJECTS; RISK FACTORS; VASODILATOR AGENTS;

EID: 33746437588     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-006-0150-y     Document Type: Article

References (35)

1. Brick R, Krzossok, Markowetz F, Schnulle P, van der Woude FJ. Braun C (2003) Acetylcysteine for prevention of contrast nephropathy: meta-analysis. Lancet 362:598-603
2. McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW (1997) Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 103:368-375
3. Gruberg L, Mintz GS, Mehran R et al (2000) The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal failure. J Am Coll Cardiol 36:1542-1548
4. Solomon R, Werner G, Mann D, D'Elia J, Silva P (1994) Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents. N Engl J Med 331:1416-1420
5. Rihal CS, Textor SC, Grill DE et al (2002) Incidence and prognostic impostance of acute renal failure after percutaneous coronary intervention. Circulation 105:2259-2264
6. Best PJ, Lennon R, Ting HH et al (2002) The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol 39:1113-1119
7. Berns AS (1989) Nephrotoxicity of contrast media. Kidney Int 36:730-740
8. Maeder M, Klein M, Fehr T, Rickli H (2004) Contrast nephropathy: review focusing on prevention. J Am Coll Cardiol 44:1763-1771
9. Brezis M, Rosen S (1995) Hypoxia of the renal medulla - Its implications for disease. N Engl J Med 332:647-655
10. Schlondorff D (1986) Renal prostaglandin synthesis: sites of production and specific actions of prostaglandins. Am J Med 81(suppl 2B):1-11
11. Heyman SN, Rosen S, Brezis M (1994) Radiocontrast nephropathy: a paradigm for the synergism between toxic and hypoxic insults in the kidney. Exp Nephrol 2:153-157
12. Sketch MH Jr, Whelton A, Schollmayer E, Koch JA, Bernink PJ, Woltering F et al (2001) Prostaglandin E1 Study Group: prevention of contrast media-induced renal dysfunction with prostaglandin E1: a randomized, double-blind, placebo-controlled study. Am J Ther 8:155-162
13. Paller MS, Manivel JC (1992) Prostaglandins protect kidneys against ischemic and toxic injury by a cellular effect. Kidney Int 42:1345-1354
14. Krause W, Muschick P, Kruger U (2002) Use of near-infrared reflection spectroscopy to study the effects of X-ray contrast media on renal tolerance in rats: effects of a prostacyclin analogue and of phosphodiesterase inhibitors. Invest Radiol 37:698-705
15. Itoh Y, Yano T, Sendo T, Oishi R (2005) Clinical and experimental evidence for prevention of acute renal failure induced by radiographic contrast media. J Pharmacol Sci 97:473-488
16. Yano T, Itoh Y, Kubota T, Sendo T, Oishi R (2004) A prostacyclin analog beraprost sodium attenuates radiocontrast media-induced LLC-PK1 cells injury. Kidney Int 65:1654-1663
17. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41
18. Solomon R (2005) The role of osmolality in the incidence of contrast induced nephropathy: a systematic review of angiographic contrast media in high risk patients. Kidney Int 68:2256-2263
19. Wigley FM, Wise RA, Seibold JR, McCloskey DA, Kujala G, Medsger TA et al (1994) Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. Ann Intern Med 120:199-206
20. Moncada S, Vane JR (1981) Prostacyclin and blood coagulation. Drugs 21:430-437
21. Zusman RM, Crow JW, Cato AE, Tolkoff-Rubin N (1981) Effects of prostacyclin infusion in uremic patients: hematologic and hemodynamic responses. Clin Pharmacol Ther 30:251-257
22. Spargias K, Alexopoulos E, Kyrzopoulos S, Iacovis P, Greenwood DC, Manginas A et al (2004) Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. Circulation 110:2837-2842
23. Heller R, Werner-Felmayer G, Werner ER (2005) Antioxidants and endothelial nitric oxide synthesis Eur J Clin Pharmacol 11:1-8 (published ahead of print), Nov
24. Rudnick MR, Goldfarb S (2003) Pathogenesis of contrast-induced nephropathy: experimental and clinical observations with an emphasis on the role of osmolality. Rev Cardiovasc Med 4:S28-S33
25. Liss P, Nygren A, Olsson U et al (1996) Effects of contrast media and mannitol on renal medullary blood flow and aggregation in the rat kidney. Kidney Int 49:1268-1275
26. Workman RJ, Shaff MI, Jackson RV, Diggs J, Frazer MG, Briscoe C (1983) Relationship of renal hemodynamic and functional changes following intravascular contrast to the renin-angiotensin system and renal prostacyclin in the dog. Invest Radiol 18:160-166
27. Turker RK, Demirel E, Ercan ZS (1988) Iloprost preserves kidney function against anoxia. Prostaglandins Leukot Essent Fat Acids 31:45-52
28. Lifschitz MD, Barnes JL (1984) Prostaglandin 12 attenuates ischemic acute renal failure in the rat. Am J Physiol 247:F714-F717
29. Agmon Y, Peleg H, Greenfeld Z, Rosen S, Brezis M (1994) Nitric oxide and prostanoids protect the renal outer medulla from radiocontrast toxicity in the rat. J Clin Invest 94:1069-1075
30. Fujita T, Fuke Y, Satomura A, Hidaka M, Ohsawa I, Endo M et al (2001) PGI2 analogue mitigates the progression rate of renal dysfunction improving renal blood flow without glomerular hyperfiltration in patients with chronic renal insufficiency. Prostagl Leukot Essent 65:223-227
31. Morgera S, Woydt R, Kern H, Schmutzler M, DeJonge K, Lun A et al (2002) Low-dose prostacyclin preserves renal function in high-risk patients after coronary bypass surgery. Crit Care Med 30:107-112
32. Boie Y, Rushmore TH, Darmon-Goodwin A, Grygorczyk R, Slipetz DM, Metters KM et al (1994) Cloning and expression of a cDNA for the human prostanoid IP receptor. J Biol Chem 269:12173-12178
33. Komhoff M, Lesener B, Nakao K, Seyberth HW, Nusing RM (1998) Localization of the prostacyclin receptor in human kidney. Kidney Int 54:1899-1908
34. Breyer MD (1998) Prostaglandin receptors in the kidney: a new route for intervention. Exp Nephrol 6:180-188
35. Yano T, Itoh Y, Kubota T, Sendo T, Koyama T, Fujita T et al (2005) A prostacyclin analog prevents radiocontrast nephropathy via phosphorylation of cyclic AMP response element binding protein. Am J Pathol 166:1333-1342